arrow
A

Alexios Matikas

karolinska institutet
H指数:24
被引数:2,250

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study
2026-06-240
OAAI
Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trial

新辅助palbociclib联合内分泌治疗与化疗在ER+/HER2-乳腺癌中的比较:一项随机II期试验

2026-04-080
OAAI
Integrating liquid biopsies and artificial intelligence for early cancer detection: A systematic review and meta-analysis

整合液体活检和人工智能用于早期癌症检测:一项系统评价和荟萃分析

2026-03-240
OAAI
Endocrine-based strategies after CDK4/6 inhibitors in biomarker-selected subgroup of hormone receptor positive advanced breast cancer: A systematic review and network meta-analysis

内分泌为基础的策略在激素受体阳性晚期乳腺癌生物标志物选择亚组中CDK4/6抑制剂后的应用:一项系统评价和网络Meta分析

2025-12-030
PRE
Prevalence and prognosis of patients with breast cancer eligible for adjuvant abemaciclib or ribociclib: a nationwide population-based study

乳腺癌患者接受阿贝西利或瑞博西利辅助治疗的患病率与预后:一项全国性基于人群的研究

2025-09-290
OAAI
Prognostic significance of tumour Ki-67 dynamics during neoadjuvant treatment in patients with breast cancer: a population-based cohort study

乳腺癌患者新辅助治疗期间肿瘤Ki-67动态变化的预后意义:一项基于人群的队列研究

2025-09-020
PREAI
Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study

风险降低手术与年轻BRCA携带者乳腺癌患者生存期的关联:一项国际队列研究

2025-05-080
PRE
Prognostic and predictive implications of sterile alpha motif and HD domain-containing protein 1 (SAMHD1) expression in breast cancer
2024-12-270
PRE
Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers
2024-09-012
OAAI